Answers are grounded in this paper and cite their sources.
Neutralizing antibody titers are important indicators of humoral immunity against herpes simplex virus type 1 (HSV-1). However, conventional plaque reduction neutralization tests (PRNTs) are labor-intensive and time-consuming. Here, we developed a rapid 96-,well fluorescence-based neutralization assay using a recombinant HSV-1-expressing copepod green fluorescent protein (HSV-1-copGFP), constructed through CRISPR/Cas9-mediated homologous recombination. The reporter virus exhibited replication kinetics comparable to those of parental HSV-1, while next-generation sequencing revealed high genomic sequence conservation across passages P5, P8, and P10. Optimized assay conditions included 100 PFU/well and a detection window of 14–16 h post-infection. A custom Python program enabled automated quantification and visual verification of GFP-positive foci. Neutralizing antibody titers showed strong correlations with conventional PRNT in murine (R2 = 0.9814, p <0.0001) and human sera (R2 = 0.9840, p <0.0001). Bland–Altman analysis further demonstrated agreement between the methods, with mean biases of −0.03760 and 0.04266 for murine and human sera, respectively. Among 24 human samples, 14 (58.33%) were positive. Specificity testing using six HSV-2-positive and six varicella-zoster virus (VZV)-positive murine sera revealed limited HSV-2 cross-neutralization (22.67–27.33% at 1:10 dilution) and negligible VZV-associated neutralization, with no samples reaching the 50% neutralization endpoint. Overall, this assay represents a promising approach for rapid and quantitative detection of HSV-1-neutralizing antibodies, with the potential to complement conventional PRNT.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: